Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Aeglea Biotherapeutics, Inc. (AGLE)  
$0.60 0.00 (0.00%) as of 4:30 Thu 9/7


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 61,170,000
Market Cap: 36.74(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.1064 - $0.6766
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Aeglea BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biotechnology company developing human enzyme therapeutics for people with rare metabolic diseases. Co.'s development programs include: Pegzilarginase in Arginase 1 Deficiency, which is a recombinant human Arginase 1 that enzymatically degrades the amino acid arginine and improves the stability and arginine-degrading activity of the enzyme in human plasma; and AGLE-177 in Homocystinuria, which is a PEGylated, or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine. Co.'s preclinical pipeline includes cystinuria program to reduce plasma cystine and cysteine levels.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 118,200
Total Buy Value $0 $0 $0 $70,494
Total People Bought 0 0 0 2
Total Buy Transactions 0 0 0 2
Total Shares Sold 0 3,435,480 3,435,480 3,435,480
Total Sell Value $0 $0 $0 $0
Total People Sold 0 1 1 1
Total Sell Transactions 0 1 1 1
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 92
  Page 1 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Harwin Peter Evan   –       •      –    2024-04-25 4 OE $0.00 $0 I/I 3,639,680 4,018,101     -
   Turtle Cameron Chief Executive Officer   •       •      –    2024-02-15 4 A $9.82 $3,928 D/D 400 746,907     -
   Harwin Peter Evan   –       •       •   2023-12-29 4 A $0.00 $0 I/I 812,076 406,038     -
   Harwin Peter Evan   –       •       •   2023-12-29 4 AS $0.00 $0 I/I (3,435,480) 0     -
   Burrows Scott L Chief Financial Officer   •       –      –    2023-12-22 4 A $0.00 $0 D/D 134,953 134,953     -
   Albers Jeffrey W.   –       •      –    2023-11-24 4/A A $0.00 $0 I/I 34,360 34,360     -
   Harwin Peter Evan   –       •       •   2023-11-24 4 A $0.00 $0 I/I 3,435,480 3,435,480     -
   Turtle Cameron Chief Executive Officer   •       •      –    2023-11-24 4 A $0.00 $0 D/D 723,440 746,507     -
   Harwin Peter Evan   –       •       •   2023-06-22 3 IO $0.00 $0 I/I 0 9,460,540 32%     
   Turtle Cameron Chief Operating Officer   •       –      –    2023-06-22 3 IO $0.00 $0 D/D 0 576,699 32%     
   Neuman Linda L Chief Medical OfficerOfficer   •       –      –    2022-11-14 3 IO $0.00 $0 D/D 0 4,000 -78%     
   Souza Marcio Director   –       •      –    2022-08-25 4 B $0.56 $50,472 D/D 90,000 90,000 2.39 -4%     
   Hanley Jr. Michael Conick Chief Commercial Officer   •       –      –    2022-06-08 4 B $0.71 $20,022 D/D 28,200 36,200 2.74 -29%     
   Quinn Anthony President & CEO   •       •      –    2022-03-16 4 B $2.34 $187,705 D/D 80,079 550,540 2.81 -83%     
   Quinn Anthony President & CEO   •       •      –    2022-03-15 4 B $1.86 $78,942 D/D 42,417 473,461 2.81 -78%     
   Quinn Anthony President & CEO   •       •      –    2022-03-14 4 B $1.93 $130,221 D/D 67,472 431,044 2.81 -77%     
   Alspaugh Jonathan Chief Financial Officer   •       –      –    2022-03-11 4 B $2.08 $156,000 D/D 75,000 165,372 2.74 -77%     
   Quinn Anthony President & CEO   •       •      –    2022-03-11 4 B $2.06 $71,780 D/D 34,777 363,572 2.81 -77%     
   Shanafelt Armen Director   –       •      –    2021-12-13 4 B $3.65 $53,600 D/D 14,685 150,000 2.39 -54%     
   Shanafelt Armen Director   –       •      –    2021-12-10 4 B $3.65 $49,333 D/D 13,516 135,315 2.39 -53%     
   Quinn Anthony President & CEO   •       •      –    2021-12-10 4 B $3.75 $39,473 D/D 10,526 328,795 2.81 -53%     
   Shanafelt Armen Director   –       •      –    2021-12-09 4 B $3.67 $446,759 D/D 121,799 121,799 2.39 -51%     
   Quinn Anthony President & CEO   •       •      –    2021-12-09 4 B $3.70 $159,500 D/D 43,108 318,269 2.81 -51%     
   Alspaugh Jonathan Chief Financial Officer   •       –      –    2021-12-09 4 B $3.72 $186,000 D/D 50,000 90,372 2.74 -51%     
   Alspaugh Jonathan Chief Financial Officer   •       –      –    2021-08-18 4 B $6.72 $48,400 D/D 7,200 40,372 2.74 -38%     

  92 Records found
  1  2  3  4   
  Page 1 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed